Land Transport (Drug Driving) Amendment Bill
Submission to Transport and Infrastructure Committee, 9 September 2024
Resources /
Submissions /
-
Submissions
- Review of the Exceptional Circumstances Framework
- Proposed changes to Special Authority criteria for empagliflozin, liraglutide, and dulaglutide
- Proposed updates to eligibility settings for publicly funded health services
- Proposed changes to the Cost or Treatment Regulations and Definitions Regulations
- Australian Medical Council’s draft accreditation standards
- Updating the Pharmaceutical Schedule
- Aged Care Ministerial Advisory Group
- MCNZ regulation of physician associates
- Draft guidance on the Privacy Code of Practices
- Proposed Arms Bill
- Funding of RSV Vaccine nirsevimab for pēpi and tamariki in Aotearoa
- MedSafe Medical Classifications Committee (MCC) 75th Meeting
- Changes to the Options for Investment list changes to the Options for Investment list
- Proposal to fund access to infliximab, etanercept, secukinumab and rituximab
- Pharmac proposal to fund another ADHD medicine to improve supply
- Funding Support for Mpox (Jynneos) Vaccine Delivery in General Practice
- Proposed amendment to Medicines Regulations to enable authorised vaccinators to administer adrenaline
- Designated pharmacist prescriber specified prescriptions medicines list
- Designated registered nurse prescriber specified prescription medicines list
- Information Privacy Principle 3A
- Funding criteria for HIV medications
- Nursing Council Scope of Practice
- Proposed National Model for Integrated Adult Palliative Care
- Proposed amendments to the designated registered nurse prescriber specified prescription medicines list
- Proposed amendments to the designated pharmacist prescriber specified prescription medicines list
- Using artificial intelligence (AI) in patient care
- Proposal to fund a new brand of methylphenidate for ADHD
- Ministry for Disabled Peoples New Zealand Disability Strategy for 2026-2030
- Proposal to fund ticagrelor for people after minor stroke or high-risk TIA
- Proposed changes to Special Authority renewal requirements
- Proposed classification of substances as controlled drugs
- Healthy Futures (Pae Ora) Amendment Bill
- Medical aspects of fitness to drive: a guide for health practitioners
- Collegial peer support and supervision framework
- MedSafe Medical Classifications Committee 74th Meeting
- Pharmac prescription changes
- COPD Guidelines 2025 update
- Draft Guidance on the Information Privacy Principle (IPP)3A notification requirements for the indirect collection of personal information
- Proposal to fully fund two liquid nutrition replacements for adults with Crohn’s disease
- Proposal to enter into a new supply agreement for the COVID-19 vaccine
- Proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD
- Draft guidance on establishing and sustaining human milk banks
- Proposal to support access to budesonide with eformoterol inhalers
- Proposal to fund Ryzodeg
- Cremation regulations review
- Putting Patients First: Modernising health workforce regulation
- Proposal to fund Mirena and Jaydess IUDs on a Practitioner Supply Order
- Migrating potential patient safety risk: Omeprazole 40mg and Flecainide 100mg capsules
- Advanced Cardiac Life Support Requirements for PGY1 Interns
- Proposal to fund the contraceptive pill desogestrel
- Proposal to widen access to medicines for blood cancer, inflammatory bowel diseases, eczema and rheumatoid arthritis
- Safety measures for the use of puberty blockers
- MedSafe Medical Classifications Committee (MCC) 73rd Meeting
- Treaty Principles Bill submission
- Unlocking the potential of active ageing
- Extension of the provisional vocational assessment period
- Proposal to increase the period of supply limit from 3 to 12 months
- Proposal to fund β-hCG low sensitivity urine test kits
- Hauora Māori Strategy
- Proposal to fund lung treatments, breast cancer, chronic obstructive pulmonary disease (COPD), prevention of RSV
- Agenda of Medicines Classification Committee meeting
- Strategy to Prevent and Minimise Gambling Harm
- Amendments to the Smokefree Environments and Regulated Products Act
- Proposal to remove the renewal criteria for stimulant treatments
- Proposal to fund lisdexamfetamine for ADHD
- Land Transport (Drug Driving) Amendment Bill
- Proposal to allow pharmacists to provide paracetamol to children under 2 years of age receiving the Bexsero vaccine
- Proposal to enable many childhood vaccinations to be given in pharmacies
- Emergency Management Bill
- Inquiry into Climate Adaptation
- Ministry of Health Precision Health
- Cost of Treatment Regulations
- Women’s Health Strategy
- The Therapeutic Products Bill
- Class B drug legislation
- Smokefree Environments and Regulated Products
- PASE whitepaper: more than a disease-based model
- Diabetes Action Plan 2022-2027
- National Screening Programmes, Breast Screen Aotearoa Service Standards
- Proposal to fund two brands of oestradiol patches
- Health and privacy information
- Proposed changes to the blood monitoring and prescribing requirements for clozapine
- MCNZ draft statements on Cultural Competency and Cultural Safety, and Hauora Māori
Also in this category
Submissions
Proposed changes to Special Authority criteria for empagliflozin, liraglutide, and dulaglutide
Submission to Pharmac
View resource
Submissions
Australian Medical Council’s draft accreditation standards
Submission to the Australian Medical Council
View resource